Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease: A Mendelian Randomization Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease : A Mendelian Randomization Study. / Emanuelsson, Frida; Nordestgaard, Børge G.; Tybjærg-Hansen, Anne; Benn, Marianne.

I: Journal of the American College of Cardiology, Bind 74, Nr. 11, 09.2019, s. 1465-1476.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Emanuelsson, F, Nordestgaard, BG, Tybjærg-Hansen, A & Benn, M 2019, 'Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease: A Mendelian Randomization Study', Journal of the American College of Cardiology, bind 74, nr. 11, s. 1465-1476. https://doi.org/10.1016/j.jacc.2019.07.037

APA

Emanuelsson, F., Nordestgaard, B. G., Tybjærg-Hansen, A., & Benn, M. (2019). Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease: A Mendelian Randomization Study. Journal of the American College of Cardiology, 74(11), 1465-1476. https://doi.org/10.1016/j.jacc.2019.07.037

Vancouver

Emanuelsson F, Nordestgaard BG, Tybjærg-Hansen A, Benn M. Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease: A Mendelian Randomization Study. Journal of the American College of Cardiology. 2019 sep.;74(11):1465-1476. https://doi.org/10.1016/j.jacc.2019.07.037

Author

Emanuelsson, Frida ; Nordestgaard, Børge G. ; Tybjærg-Hansen, Anne ; Benn, Marianne. / Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease : A Mendelian Randomization Study. I: Journal of the American College of Cardiology. 2019 ; Bind 74, Nr. 11. s. 1465-1476.

Bibtex

@article{956a9e3d327e49e29c9cf4945d7c598e,
title = "Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease: A Mendelian Randomization Study",
abstract = "Background: Low-density lipoprotein cholesterol (LDL-C) is causally associated with a high risk of coronary artery disease. Whether this also holds for a spectrum of peripheral vascular diseases is unknown. Objectives: The purpose of this study was to determine whether high LDL-C causally relates to risk of retinopathy, neuropathy, chronic kidney disease (CKD), and peripheral arterial disease (PAD) in the general population. Methods: One-sample Mendelian randomization (MR) of 116,419 Danish individuals, 2-sample MR on summary-level data from the Global Lipid Genetics Consortium (GLGC) (n = 94,595) and the UK Biobank (n = 408,455), and meta-analysis of randomized statin trials (n = 64,134) were performed. Results: Observationally, high LDL-C did not associate with high risk of retinopathy or neuropathy. There were stepwise increases in risk of CKD and PAD with higher LDL-C (both p for trend <0.001), with hazard ratios of 1.05 (95% confidence interval [CI]: 0.97 to 1.13) for CKD, and 1.41 (95% CI: 1.23 to 1.62) for PAD in individuals with LDL-C above the 95th percentile versus below the 50th percentile. In genetic, causal analyses in the Copenhagen studies, the risk ratio of disease for a 1 mmol/l higher LDL-C was 1.06 (95% CI: 0.24 to 4.58) for retinopathy, 1.05 (95% CI: 0.64 to 1.72) for neuropathy, 3.83 (95% CI: 2.00 to 7.34) for CKD, and 2.09 (95% CI: 1.30 to 2.38) for PAD. Summary-level data from the GLGC and the UK Biobank for retinopathy, neuropathy, and PAD gave similar results. For CKD, a 1-mmol/l lower LDL-C conferred a higher eGFR of 1.95 ml/min/1.73 m2 (95% CI: 1.88 to 2.02 ml/min/1.73 m2) observationally, 5.92 ml/min/1.73 m2 (95% CI: 4.97 to 6.86 ml/min/1.73 m2) genetically, and 2.69 ml/min/1.73 m2 (95% CI: 1.48 to 3.94 ml/min/1.73 m2) through statin therapy. Conclusions: High LDL-C was not causally associated with risk of retinopathy and neuropathy; however, high LDL-C was observationally and genetically associated with high risks of PAD and CKD, suggesting that LDL-C is causally involved in the pathogenesis of these diseases.",
keywords = "chronic kidney disease, LDL-C, Mendelian randomization, meta-analysis, neuropathy, peripheral arterial disease, retinopathy",
author = "Frida Emanuelsson and Nordestgaard, {B{\o}rge G.} and Anne Tybj{\ae}rg-Hansen and Marianne Benn",
year = "2019",
month = sep,
doi = "10.1016/j.jacc.2019.07.037",
language = "English",
volume = "74",
pages = "1465--1476",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier",
number = "11",

}

RIS

TY - JOUR

T1 - Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease

T2 - A Mendelian Randomization Study

AU - Emanuelsson, Frida

AU - Nordestgaard, Børge G.

AU - Tybjærg-Hansen, Anne

AU - Benn, Marianne

PY - 2019/9

Y1 - 2019/9

N2 - Background: Low-density lipoprotein cholesterol (LDL-C) is causally associated with a high risk of coronary artery disease. Whether this also holds for a spectrum of peripheral vascular diseases is unknown. Objectives: The purpose of this study was to determine whether high LDL-C causally relates to risk of retinopathy, neuropathy, chronic kidney disease (CKD), and peripheral arterial disease (PAD) in the general population. Methods: One-sample Mendelian randomization (MR) of 116,419 Danish individuals, 2-sample MR on summary-level data from the Global Lipid Genetics Consortium (GLGC) (n = 94,595) and the UK Biobank (n = 408,455), and meta-analysis of randomized statin trials (n = 64,134) were performed. Results: Observationally, high LDL-C did not associate with high risk of retinopathy or neuropathy. There were stepwise increases in risk of CKD and PAD with higher LDL-C (both p for trend <0.001), with hazard ratios of 1.05 (95% confidence interval [CI]: 0.97 to 1.13) for CKD, and 1.41 (95% CI: 1.23 to 1.62) for PAD in individuals with LDL-C above the 95th percentile versus below the 50th percentile. In genetic, causal analyses in the Copenhagen studies, the risk ratio of disease for a 1 mmol/l higher LDL-C was 1.06 (95% CI: 0.24 to 4.58) for retinopathy, 1.05 (95% CI: 0.64 to 1.72) for neuropathy, 3.83 (95% CI: 2.00 to 7.34) for CKD, and 2.09 (95% CI: 1.30 to 2.38) for PAD. Summary-level data from the GLGC and the UK Biobank for retinopathy, neuropathy, and PAD gave similar results. For CKD, a 1-mmol/l lower LDL-C conferred a higher eGFR of 1.95 ml/min/1.73 m2 (95% CI: 1.88 to 2.02 ml/min/1.73 m2) observationally, 5.92 ml/min/1.73 m2 (95% CI: 4.97 to 6.86 ml/min/1.73 m2) genetically, and 2.69 ml/min/1.73 m2 (95% CI: 1.48 to 3.94 ml/min/1.73 m2) through statin therapy. Conclusions: High LDL-C was not causally associated with risk of retinopathy and neuropathy; however, high LDL-C was observationally and genetically associated with high risks of PAD and CKD, suggesting that LDL-C is causally involved in the pathogenesis of these diseases.

AB - Background: Low-density lipoprotein cholesterol (LDL-C) is causally associated with a high risk of coronary artery disease. Whether this also holds for a spectrum of peripheral vascular diseases is unknown. Objectives: The purpose of this study was to determine whether high LDL-C causally relates to risk of retinopathy, neuropathy, chronic kidney disease (CKD), and peripheral arterial disease (PAD) in the general population. Methods: One-sample Mendelian randomization (MR) of 116,419 Danish individuals, 2-sample MR on summary-level data from the Global Lipid Genetics Consortium (GLGC) (n = 94,595) and the UK Biobank (n = 408,455), and meta-analysis of randomized statin trials (n = 64,134) were performed. Results: Observationally, high LDL-C did not associate with high risk of retinopathy or neuropathy. There were stepwise increases in risk of CKD and PAD with higher LDL-C (both p for trend <0.001), with hazard ratios of 1.05 (95% confidence interval [CI]: 0.97 to 1.13) for CKD, and 1.41 (95% CI: 1.23 to 1.62) for PAD in individuals with LDL-C above the 95th percentile versus below the 50th percentile. In genetic, causal analyses in the Copenhagen studies, the risk ratio of disease for a 1 mmol/l higher LDL-C was 1.06 (95% CI: 0.24 to 4.58) for retinopathy, 1.05 (95% CI: 0.64 to 1.72) for neuropathy, 3.83 (95% CI: 2.00 to 7.34) for CKD, and 2.09 (95% CI: 1.30 to 2.38) for PAD. Summary-level data from the GLGC and the UK Biobank for retinopathy, neuropathy, and PAD gave similar results. For CKD, a 1-mmol/l lower LDL-C conferred a higher eGFR of 1.95 ml/min/1.73 m2 (95% CI: 1.88 to 2.02 ml/min/1.73 m2) observationally, 5.92 ml/min/1.73 m2 (95% CI: 4.97 to 6.86 ml/min/1.73 m2) genetically, and 2.69 ml/min/1.73 m2 (95% CI: 1.48 to 3.94 ml/min/1.73 m2) through statin therapy. Conclusions: High LDL-C was not causally associated with risk of retinopathy and neuropathy; however, high LDL-C was observationally and genetically associated with high risks of PAD and CKD, suggesting that LDL-C is causally involved in the pathogenesis of these diseases.

KW - chronic kidney disease

KW - LDL-C

KW - Mendelian randomization

KW - meta-analysis

KW - neuropathy

KW - peripheral arterial disease

KW - retinopathy

UR - http://www.scopus.com/inward/record.url?scp=85071539132&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2019.07.037

DO - 10.1016/j.jacc.2019.07.037

M3 - Journal article

C2 - 31514949

AN - SCOPUS:85071539132

VL - 74

SP - 1465

EP - 1476

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 11

ER -

ID: 240200145